NITROSAMINE IMPURITIES IN MEDICINES: FORMATION, TOXICITY, REGULATIONS, AND CONTROL
Keywords:
nitrosamines, pharmaceuticals, pharmaceutical regulation, quality control, risk assessment, toxicityAbstract
Nitrosamines are a class of N-nitroso compounds with high thermal and aqueous stability, considered potential carcinogenic and mutagenic substances. They are formed when secondary or tertiary amines react with nitrosating agents (nitrites) under acidic conditions. The detection of N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), and other nitrosamines in drugs such as valsartan, ranitidine, and metformin has led to product recalls and strict regulatory measures by the FDA, EMA, and WHO.
This paper analyzes the mechanisms of formation, toxicity, sources of contamination, regulatory frameworks, and best practices for risk management, with the aim of ensuring the safety of pharmaceutical products and protecting patient health.
References
Bharate, S. S. (2021). Critical analysis of drug product recalls due to nitrosamine impurities. Journal of Medicinal Chemistry, 64(6), 2923–2936. https://doi.org/10.1021/acs.jmedchem.0c02126
Chourasiya, S. S., & Ranbhan, K. J. (2022). Nitrosamine impurities in APIs: A comprehensive review. International Journal of Pharmacy and Biological Sciences, 12(1), 145–157. https://doi.org/10.21276/ijpbs.2022.12.1.18
Eisenbrand, G., Spiegelhalder, B., Kann, J., Klein, R., & Preussmann, R. (1979). Carcinogenic N-nitrosodimethylamine as a contamination in drugs containing 4-dimethylamino-2,3-dimethyl-1-phenyl-3-pyrazolin-5-one (amidopyrine, aminophenazone). Arzneimittelforschung, 29(6), 867–869.
European Medicines Agency. (2019). Questions and answers on nitrosamines for marketing authorisation holders (EMA/CHMP/428592/2019). https://www.ema.europa.eu/en/documents
European Medicines Agency. (2020). Questions and answers on nitrosamine impurities in human medicinal products (EMA/409815/2020 Rev.12). https://www.ema.europa.eu
European Medicines Agency. (2020). Ranitidine-containing medicinal products. https://www.ema.europa.eu/en/medicines/human/referrals/ranitidine-containing-medicinal-products
European Medicines Agency. (2021). Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group. https://www.ema.europa.eu/en/medicines/human/referrals/angiotensin-iireceptor-antagonists-sartans-containing-tetrazole-group
Florian, J., Matta, M. K., DePalma, R., Gershuny, V., Patel, V., Hsiao, C.-H., Zusterzeel, R., Rouse, R., Prentice, K., Nalepinski, C. G., Kim, I., Yi, S., Zhao, L., Yoon, M., Selaya, S., Keire, D., Korvick, J., & Strauss, D. G. (2021). Effect of oral ranitidine on urinary excretion of N-nitrosodimethylamine (NDMA): A randomized clinical trial. JAMA, 326(3), 240–249. https://doi.org/10.1001/jama.2021.7393
International Agency for Research on Cancer. (1978). Some N-nitroso compounds (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 17). https://monographs.iarc.who.int/wp-content/uploads/2018/06/mono17.pdf
International Agency for Research on Cancer. (1980). General considerations on N-nitrosatable drugs (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 24). IARC.
International Council for Harmonisation. (2018). Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk (ICH M7(R1) guideline). https://www.ich.org/page/m7-impurities-guideline
King, F. J., Searle, A. D., & Urquhart, M. W. R. (2020). Ranitidine – Investigations into the root cause for the presence of N-nitroso-N,N-dimethylamine in ranitidine hydrochloride drug substances and associated drug products. Organic Process Research & Development, 24(12), 2915–2926. https://doi.org/10.1021/acs.oprd.0c00427
Rojsitthisak, P., et al. (2023). An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals. Saudi Pharmaceutical Journal, 31(2), 295–311. https://doi.org/10.1016/j.jsps.2022.12.001
U.S. Food and Drug Administration. (2020). Control of nitrosamine impurities in human drugs – Guidance for industry. https://www.fda.gov/media/141720/download
U.S. Food and Drug Administration. (2020). FDA updates and press releases on nitrosamine impurities in ARBs, ranitidine, metformin, and rifampin. https://www.fda.gov/drugs/drug-safety-and-availability/information-about-nitrosamine-impurities-medications
World Health Organization. (2019). WHO medical product alert No. 2/2019: Update on nitrosamine impurities (NDMA in valsartan and beyond). https://www.who.int/news/item/11-04-2019-medical-product-alert-n-2-2019
